308 Shares in Humana Inc. (NYSE:HUM) Bought by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich bought a new position in Humana Inc. (NYSE:HUM) during the fourth quarter, HoldingsChannel reports. The fund bought 308 shares of the insurance provider’s stock, valued at approximately $86,000.

A number of other institutional investors have also bought and sold shares of HUM. Janney Montgomery Scott LLC increased its stake in Humana by 11.6% in the 3rd quarter. Janney Montgomery Scott LLC now owns 3,721 shares of the insurance provider’s stock worth $1,179,000 after buying an additional 388 shares in the last quarter. Van ECK Associates Corp purchased a new stake in Humana in the 3rd quarter worth $424,000. Assetmark Inc. increased its stake in Humana by 19.4% in the 3rd quarter. Assetmark Inc. now owns 14,723 shares of the insurance provider’s stock worth $4,663,000 after buying an additional 2,392 shares in the last quarter. Atria Investments Inc increased its stake in Humana by 18.1% in the 3rd quarter. Atria Investments Inc now owns 5,552 shares of the insurance provider’s stock worth $1,759,000 after buying an additional 851 shares in the last quarter. Finally, Crossmark Global Holdings Inc. increased its stake in Humana by 5.0% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 8,153 shares of the insurance provider’s stock worth $2,583,000 after buying an additional 388 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Down 0.4 %

Shares of NYSE HUM opened at $250.21 on Wednesday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The company has a market cap of $30.19 billion, a P/E ratio of 25.15, a PEG ratio of 2.05 and a beta of 0.57. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The firm has a 50-day simple moving average of $271.67 and a two-hundred day simple moving average of $281.65.

Humana (NYSE:HUM) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.41%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio is presently 35.58%.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. JPMorgan Chase & Co. cut their price target on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday, February 18th. Barclays raised their price objective on Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Royal Bank of Canada restated an “outperform” rating and set a $283.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Piper Sandler raised their price objective on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Finally, StockNews.com lowered Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Twenty research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.